Betta Pharmaceuticals Co., Ltd. (SHE:300558)

Market Cap	22.24B
Revenue (ttm)	2.76B
Net Income (ttm)	459.57M
Shares Out	418.49M
EPS (ttm)	1.09
PE Ratio	48.80
Forward PE	30.90
Dividend	0.17 (0.32%)
Ex-Dividend Date	Jun 6, 2024

Volume	11,307,307
Average Volume	5,439,181
Open	52.91
Previous Close	52.98
Day's Range	52.60 - 54.75
52-Week Range	30.43 - 59.88
Beta	0.84
RSI	54.64
Earnings Date	Apr 18, 2025

About Betta Pharmaceuticals

Betta Pharmaceuticals Co., Ltd. researches and develops, manufactures, and markets medicines for the treatment of cancer in China. The company offers Icotinib hydrochloride, an oral epidermal growth factor receptor tyrosine kinase inhibitor, which is used to treat non-small-cell lung cancer; and Ensartinib hydrochloride, an anaplastic lymphoma kinase inhibitor for the treatment of non-small cell lung cancer. The company was founded in 2003 and is headquartered in Hangzhou, China.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2003
• Employees: 1,961
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300558

Financial Performance

In 2023, Betta Pharmaceuticals's revenue was 2.46 billion, an increase of 3.35% compared to the previous year's 2.38 billion. Earnings were 348.03 million, an increase of 139.33%.